Last Price$68.96NASDAQ Previous Close - Last Trade as of 4:00PM ET 3/27/20

Today's Change-4.09(5.60%)
Bid (Size)$66.61 (73)
Ask (Size)$68.96 (1)
Day Low / High$68.55 - 72.16
Volume1.5 M

View Biotechnology IndustryPeer Comparison as of 03/27/2020


Incyte Corp ( NASDAQ )

Price: $68.96
Change: -4.09 (5.60%)
Volume: 1.5 M
4:00PM ET 3/27/2020

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $79.51
Change: -3.13 (3.79%)
Volume: 1.4 M
4:15PM ET 3/27/2020

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $104.21
Change: +0.01 (0.01%)
Volume: 719.9 K
4:00PM ET 3/27/2020

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $84.01
Change: -2.13 (2.47%)
Volume: 2.5 M
4:15PM ET 3/27/2020

Seattle Genetics Inc ( NASDAQ )

Price: $109.27
Change: -6.87 (5.92%)
Volume: 1.0 M
4:00PM ET 3/27/2020

Read more news Recent News

2020, 2021, and Q1 Earnings Estimates for Incyte Trimmed
1:55AM ET 3/26/2020 MT Newswires

Incyte Corp's (NASDAQ:INCY, Recent Price: 67.43) forecasted earnings estimates for Q1 ending March 31, 2020, and the expectations for 2020 and 2021 have...

--Analyst Actions: Oppenheimer Cuts Incyte's PT to $85 From $99 as COVID-19 Interrupts Office Visits, New Prescriptions; Outperform Rating Kept
10:21AM ET 3/25/2020 MT Newswires

Price: 68.04, Change: +0.61, Percent Change: +0.90 ...

Eli Lilly, Incyte Secure Breakthrough Therapy Designation for Alopecia Areata Drug
7:13AM ET 3/16/2020 MT Newswires

Eli Lilly and Company (LLY) and Incyte (INCY) said Monday that baricitinib has received a breakthrough therapy designation with the US Food and Drug...

--Analyst Actions: BofA Securities Upgrades Incyte to Buy From Neutral, Sets $83 Price Target
11:57AM ET 3/13/2020 MT Newswires

Price: 69.82, Change: +1.80, Percent Change: +2.65 ...

View all Commentary and Analysis

Kadmon Holdings: Pick Up This Late-Stage Biopharmaceutical Company In March 2020
12:04PM ET 3/14/2020 Seeking Alpha

Syros, Beyond Oncology
9:00AM ET 3/13/2020 Seeking Alpha

Week In Review: Abpro Bio Signs $1.1 Billion Deal For China-Asian Rights To 2 Bi-Specifics
1:59PM ET 3/08/2020 Seeking Alpha

Bouncing Biotechs: A Multi-Company Review
9:53AM ET 2/24/2020 Seeking Alpha

Company Profile

Business DescriptionIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. View company web site for more details
Address1801 Augustine Cut-Off
Wilmington, Delaware 19803
Number of Employees1,367
Recent SEC Filing03/26/20208-K
Chairman, President & Chief Executive OfficerHervé Hoppenot
Chief Financial Officer & Executive Vice PresidentChristiana Stamoulis
Chief Medical Officer & Executive Vice PresidentSteven H. Stein
Chief Scientific Officer & Executive VPDashyant Dhanak

Company Highlights

Price Open$71.20
Previous Close$73.05
52 Week Range$62.48 - 96.79
Market Capitalization$14.9 B
Shares Outstanding216.8 M
SectorHealth Technology
Next Earnings Announcement05/05/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings33.64
Earnings per Share$2.01
Beta vs. S&P 500N/A
Revenue$1.9 B
Net Profit Margin20.70%
Return on Equity19.11%

Analyst Ratings as of 03/23/2020

Consensus RecommendationConsensus Icon
Powered by Factset